NASDAQ:EVGN - Evogene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.18 -0.06 (-2.68 %)
(As of 02/22/2019 02:00 PM ET)
Previous Close$2.2405
Today's Range$2.18 - $2.24
52-Week Range$1.98 - $4.18
Volume3,922 shs
Average Volume3,110 shs
Market Capitalization$56.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company operates in the United States, Germany, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, ICL, Monsanto, Bayer, and others. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.38 million
Book Value$2.69 per share

Profitability

Net Income$-20,830,000.00
Net Margins-1,147.40%

Miscellaneous

Employees205
Market Cap$56.14 million
Next Earnings Date2/27/2019 (Estimated)
OptionableNot Optionable

Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) released its earnings results on Tuesday, May, 29th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company had revenue of $0.37 million for the quarter. Evogene had a negative net margin of 1,147.40% and a negative return on equity of 33.97%. View Evogene's Earnings History.

When is Evogene's next earnings date?

Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Evogene.

Has Evogene been receiving favorable news coverage?

Headlines about EVGN stock have been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Evogene earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days.

Who are some of Evogene's key competitors?

What other stocks do shareholders of Evogene own?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:
  • Mr. Ofer Haviv, CEO & Pres (Age 53)
  • Ms. Dorit Kreiner, Interim Chief Financial Officer
  • Mr. Mark Kapel, Exec. VP of Technology (Age 42)
  • Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)
  • Ms. Sigal Fattal, Exec. Officer (Age 48)

Who are Evogene's major shareholders?

Evogene's stock is owned by many different of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.14%).

Which institutional investors are buying Evogene stock?

EVGN stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $2.18.

How big of a company is Evogene?

Evogene has a market capitalization of $56.14 million and generates $3.38 million in revenue each year. Evogene employs 205 workers across the globe.

What is Evogene's official website?

The official website for Evogene is http://www.evogene.com.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (NASDAQ EVGN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel